In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix 4C and commentary on the Company’s progress toward the first in-human clinical studies of its proprietary MagSense® technology.
View Imagion Biosystems December 2017 Quarterly Update.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)